21
Dec
2016
Tag: immuno-oncology
8
Dec
2016
Bionest
Moonshot: On its Way
On September 17, Vice President Joe Biden released his final report on the Cancer Moonshot before leaving office. He announced progress on over 20 programs now underway during the effort’s first year or soon to be launched, and another two dozen for the second year of the effort and beyond. Back in September we...
14
Nov
2016
Bionest
From Disease Treatment to Patient Care: Thoughts from ESMO 2016
The theme of patient centricity and care that we discussed at this year’s ASCO continued this autumn at ESMO 2016. The tagline of the conference was ‘From disease treatment to patient care,’ which according to the organizers, “intended to capture and integrate clinical research with patient needs, and reinforces our commitment to bring the best...
5
Oct
2016
Bionest
Chan Zuckerberg Initiative Funds $3 Billion Science Effort to Cure or Manage All Diseases by 2100
On September 21, Facebook CEO and billionaire, Mark Zuckerberg, and his pediatrician wife, Dr. Priscilla Chan, announced a new, privately funded big science effort. The couple pledged more than $3 billion toward a plan to “cure, prevent or manage all disease within our children’s lifetime.” The couple has pledged to donate over $3 billion...
29
Sep
2016
Bionest
Blue Ribbon Panel Issues Cancer Moonshot Recommendations
On September 7, a Blue Ribbon Panel — composed of 28 top cancer researchers, oncologists, patient advocates and leaders from the private sector — issued 10 recommendations aimed at speeding up advances in cancer prevention, diagnosis, treatment and care. The panel was created as part of the Cancer Moonshot first announced in January of this...
14
Sep
2016
Bionest
PRIME Launched by EMA to Speed Review and Approval of Innovative, “Breakthrough” Drugs
Four years ago, the US Food and Drug Administration launched its “breakthrough designation” program, designed to speed the review and potential approval of new therapeutics deemed to offer the possibility of substantial improvement over existing options for patients with life-threatening or serious diseases. Since then, the FDA has approved more than 30 drugs in this category, many...
2
Aug
2016
Bionest
Update on the “Cancer Moonshot”
In March, we wrote about the “Cancer Moonshot” Initiative that was announced as part of President Obama’s 2016 State of the Union Address. Headed by Vice President Joe Biden, the aim of the initiative was to facilitate collaboration in cancer research, treatment, detection and prevention and to facilitate a decade’s worth of advances over the...
6
Jul
2016
Bionest
Collective Wisdom Around Oncology – Comments on ASCO 2016
The Bionest Oncology team spent a jam packed and exciting five days at ASCO 2016 earlier this month in Chicago. More than 30,000 oncology professionals gathered from all around the world to discuss the latest data and innovations in oncology, and it did not disappoint. The theme of ASCO this year was Collective Wisdom, which...
3
Jun
2016
Bionest
Some Thoughts on the Latest Immuno-oncology Approval
On May 18, the U.S. Food and Drug Administration approved the latest immunotherapeutic drug, atezolizumab (Tecentriq), from Roche’s California division, Genentech. The drug, a PD-L1 inhibitor, is the first product in its class to gain approval for a common form of bladder cancer, urothelial carcinoma — specifically for patients with advanced disease or those who...
27
May
2016